Dr. Thomas Buckley (2002 Research Grant)

Although, chemotherapy is a popular cancer therapy, it is not as effective for prostate cancer. Chemotherapy is also harmful to healthy cells. As a result, it is not a popular treatment for prostate cancer. In 2002 we granted Dr. Thomas Buckley funds to research a prostate cancer-specific toxin. His work has been very successful; he has developed a drug called PRX302 which selectively and effectively kills PSA-producing cells without harming other tissues.

The results of the initial study were so encouraging that a company, called Protox Therapeutics, was formed to further develop the idea and hopefully bring the discovery to market. The drug is now in phase II clinical trails.